Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MARS1 | P56192 | 1/20 | 0.69 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.53 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL178915 | 0.85 | MARS1 (0.65) | MARS1DNM1PLA2G1BPOLBATG4B | |
| SCHEMBL7807042 | 0.85 | MARS1 (0.65) | MARS1DNM1PLA2G1BPOLBATG4B | |
| SCHEMBL5668528 | 0.84 | MARS1 (0.64) | MARS1DNM1CNR1 | |
| SCHEMBL7815628 | 0.83 | MARS1 (0.87) | MARS1 | |
| SCHEMBL178914 | 0.81 | MARS1 (1.00) | MARS1 | |
| SCHEMBL7821091 | 0.81 | MARS1 (0.96) | MARS1 | |
| SCHEMBL7815681 | 0.81 | MARS1 (0.69) | MARS1CNR1 | |
| SCHEMBL7807655 | 0.81 | MARS1 (0.69) | MARS1CNR1 | |
| Hydrochloric Acid SCHEMBL7821357 | 0.81 | MARS1 (0.98) | MARS1 | |
| SCHEMBL7806974 | 0.81 | MARS1 (0.94) | MARS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120058133-A1 | INHIBITION OF TRNA SYNTHETASES AND THERAPEUTIC APPLICATIONS THEREOF | AARS1, GARS1, TRMT1 | MARS1 55/4885DNM1 3491/4885PLA2G1B 3168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.